Dr Chris DavisGeneral Manager克里斯戴维斯博士糖组学研究院总经理

Institute for Glycomics

Fighting diseases of global impact糖组学研究院

InstituteforGlycomics,GriffithUniversity

Institute for Glycomics世界一流的生物医学研究糖组学研究院

Vision 目标

To establish the world’s preeminent Glycomics Research

Institute for the discovery and development of novel

drugs, vaccines and diagnostics for Infectious Diseases

and Cancer.

创建世界知名糖组学研究院，从而探索研发新型药

物、疫苗以及传染性疾病与癌症的诊断方法

Institute for Glycomics世界一流的生物医学研究糖组学研究院

• Our Institute comprises an appropriate mix

of over 200 clinical and basic research

scientists, expanding fundamental

knowledge to discover and develop new

drugs, vaccines and diagnostics within the

Institute.

• 研究院成员由200多个临床研究科学家及

基础研究科学家组成，大家在此拓展基础

知识以探索研发新型药物、疫苗与诊断方

法。

Institute for Glycomics世界一流的生物医学研究糖组学研究院

• Our size and multi-disciplinary research

portfolio provides a one-stop-shop for drug,

vaccine and diagnostic discovery and

development. It also provides a critical mass

for significant international engagement.

• 我们的规模与跨学科研究组合项目为探索和研发药物、疫苗以及诊断

方法提供了一站式服务。同时也提

供了大量重大国际合作的机会。

Glycomics is the study of carbohydrates or sugars and their essential role in maintaining healthy life and in various

diseases

糖组学研究碳水化合物或糖类，以及研究它们在维持健康与众疾病中扮演的关键角色

Every cell in our body is decorated with sugars

人体中的每一个细胞都含有糖

Sugars allow cells in the human body to do a number of things including to talk to each other

糖促使人体细胞得以完成许多事情，其中包括互相交谈

What is Glycomics?什么是糖组学

SugarCoat

CellLayer

0.2µm2µm

What is Glycomics?什么是糖组学

Diseases such as infectious diseases (for example influenza) and cancers (for example lung cancer) take advantage or

alter the role of sugars in maintaining healthy life and ageing.

诸如传染性疾病（例如流感）和癌症（例如肺癌）等的疾病是利用或改变了糖在维持生命健康以及衰老过程中

的角色。

Using this knowledge of the role of sugars in disease, we invent new drugs, vaccines and diagnostics to treat, prevent

or diagnose cancer and infectious diseases

我们利用已知的糖在疾病中的作用这一知识，来发明新药物、疫苗以及诊断方法来治疗、预防或诊断癌症以及

传染性疾病

What is Glycomics?什么是糖组学

Over many decades ‘Genomics’ has helped to deliver new medicines.

Glycomics is the new era in science that will provide new drugs, vaccines and diagnostics.

多年来，“基因组学”已成功协助制造了许多新药物。

糖组学是科学中的新领域，可以为我们提供新药物、疫苗与诊断方法

What is Glycomics?什么是糖组学

Track record in commercialisation of drugs and vaccines 糖组学研究院 药物与疫苗商业化所取得的成绩

It was the Glycomics Approach that led to the discovery of the world’s first anti-influenza drug, Zanamivir

(Relenza®; GSK) by the Institute‘s inaugural and current Director, Professor Mark von Itzstein

全球首个抗流感药物Zanamivir (Relenza®; GSK) 就是由研究院现任主任Mark von Itzstein教授通过糖组学的

方法研发出来的

Relenza peak sales 2009 (US $1.1 billion)

Relenza 2009年的销量达到峰值（11亿美元）

Translational Research Capacity糖组学研究院 转化性研究能力

Discovery Facilities研发设备

GMP Manufacture (biologicals)GMP生产(生物制剂)

Phase 1 Human Clinical Trials第一阶段人类临床试验

Preclinical Development临床使用前研发

Translational Focus – recent deal history糖组学研究院 转化性研究能力

Sirtex Medical Limited- Small molecule drug candidate for sepsis- Licence and co-development agreement

- Phase 1 clinical trial currently underway

Dextra – glycan array product- Manufacture and distribution agreement

- Manufactured at the Institute and went on sale globally in June 2016

Paradigm Biopharmaceuticals – Drug candidate for alphaviral diseases - Licence and subsequent consulting agreement

- Phase 2 clinical trial currently underway

Olymvax Biopharmaceuticals – Vaccine candidate for Group A Streptococcus

- Licence and co-development agreement

- Currently in preclinical development

- Progress to GMP manufacture and clinical trials over the next 18 months

InstituteforGlycomics,GriffithUniversity

Diverse Technology Portfolio 糖组学研究院 多样化投资组合

Institute for Glycomics Existing Drug and Vaccine Development Pipeline (V=Vaccine, D=Drug)

Discovery Pre-Clinical Phase I Phase II Phase III Significance

Human Infectious Disease Malaria (V) Vaccine market estimated at USD1.62 billion in 20251. Causes 584,000 deaths annually2.

Group A Streptococcus (V) Causes more than 500,000 deaths per year worldwide3. Parainfluenza (D) Economic burden to society exceeds USD200 million per annum in the US4.

Gonorrhoea (V) Global annual incidence of 88 million5. Influenza (D) Seasonal influenza vaccine market estimated to be worth USD3.8 billion in 20186.

Chikungunya Virus (V) Cause of chronic joint pain7. >1 million cases reported in the Americas in 20148. Hand, Foot and Mouth Disease (D) Worldwide annual incidence of 2.89 million9.

Group B Meningococcal (V) Market estimated at USD3.76 billion in 201910. Up to 10% of cases are fatal11. Human Metapneumovirus (D) Leading cause of acute respiratory illness in children12.

Respiratory Syncytial Virus (D) 75-125,000 infants in the US hospitalised annually13. Dengue Virus (D) 50-100 million cases of infection each year globally14.

Ross River Virus (D) An emerging cause of viral arthralgia affecting more 4,400 people per year15. Rotavirus (D) Accounts for approximately 5% of child deaths annually16.

Hendra Virus (D) An emerging human pathogen with a mortality rate greater than 50% in humans17. Campylobacter jejuni (V) Leading global cause of food-borne gastroenteritis18.

Tuberculosis (D) 1.5 million deaths in 2013 – making it the second greatest single infectious agent killer19. Non-typeable Haemophilus influenza

(V) A common cause of localised respiratory tract disease in children20.

Moraxella catarrhalis (V) Significant cause of respiratory tract infection21.

Cancer Melanoma (D) Market estimated at USD10.4 billion in 200922.

Metastatic cancer (D) 20-30% of cancer patients develop metastatic cancer23,24,25. Acute Lymphoblastic Leukaemia (D) The most common childhood cancer26

Non-Hodgkin’s Lymphoma (D) Killed 210,000 people worldwide in 201027

Autoimmune Disease

Global prevalence of 35m in 201328 Type-1 and Type-2 Diabetes (D) Global prevalence of 382 million people in 201329.

AUSTRALIAN CENTRE FOR CANCER GLYCOMICS

(A2CG)

1 2

3Non-TumorTumor

Non-TumorTumor

CARBOHYDRATE LANGUAGE CHANGES IN CANCER?

Fingerprinting cancers by Glycomics

Institute for GlycomicsContact糖组学研究院联系方式

Dr Chris Davis 克里斯戴维斯博士 email （电子邮件）: chris.davis@griffith.edu.au

General Manager 总经理 phone （电话）: +617 555 27033

THANK YOU谢谢